Novartis faced a fresh scandal this week with revelations AveXis scientists manipulated Zolgensma data. On Wednesday, execs responded with their side of the story. More: Novartis CEO: 'We did the best we could' in Zolgensma data manipulation probe Source: fierce
read moreKnown for aggressive buyouts of its own, CDMO Cambrex is now the target of a buyout bid—this time to the tune of $2 billion. More: CDMO Cambrex flips its aggressive buyout script with B sale to Permira Funds Source: fierce
read moreMerck and AstraZeneca said they have seen positive results from a phase 3 trial of their PARP inhibitor Lynparza in men with mutated metastatic castration-resistant prostate cancer. It could give the partners a leg up in an ongoing battle for
read moreTeva’s CEO Kåre Schultz has had his hands full since taking the helm in 2017. Now, he needs to locate his next finance chief. More: Teva scouts new CFO as McClellan steps down for personal reasons Source: fierce
read moreAllergan has confirmed it will hive off two drugs to help AbbVie’s $63 billion takeover pass U.S. antitrust scrutiny. But recent regulatory decisions—and indecision—on pharma deals has analysts worried whether those selloffs would be enough. More: Is Allergan unloading 2
read moreThe drug is recommended provided that Herceptin (trastuzumab) is the only HER2-directed adjuvant treatment people have had. More: New early breast cancer option recommended by NICE Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals